Market data including bonds and fuel prices
That turnip Mapisa-Nqakula has confirmed beyond any doubt that the party cannot be renewed or rehabilitated
But advocate Mpofu says justices must accept former prisons chief granted parole correctly
Provincial chair elect indicates he will support Ramaphosa’s re-election as ANC president
Business Day TV talks to independent analyst Loyiso Mpeta
Consumer finances crumble under the pressure of rising prices and interest rates, Unisa vulnerability report shows
Some in the industry believe a ban on the export of scrap will mean a more competitive steel industry, with lower prices passed on to consumers
Washington targets chief of staff Nathaniel McGill, chief prosecutor Sayma Syrenius Cephus and Bill Twehway, MD of Liberia’s National Port Authority
Veteran seamer believes he still has plenty to offer despite turning 40
Porsche Taycan Turbo S laps the famous German circuit in seven minutes and 33 seconds
London — GlaxoSmithKline (GSK), Britain’s biggest drug maker, faces more top management change with chief financial officer Simon Dingemans retiring in 2019.
The former Goldman Sachs investment banker, who joined in 2011, will step down from the board in May 2019, the company said on Wednesday.
As Dingemans’s departure is voluntary he will not receive a severance payment.
The group said it planned to look both internally and externally to identify a successor. The departure provides a further opportunity for CEO Emma Walmsley to stamp her imprint on the group as she tries to increase sales and improve productivity in the core pharmaceuticals division.
Walmsley, who took over in April 2017, has already appointed a new head of pharmaceuticals in Luke Miels and a new head of drug research in Hal Barron, as well as making Karenann Terrell the head of digital operations, an area within Dingemans’s orbit.
In his time at GSK, Dingemans has helped oversee two transformational deals with Nov...
A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.
Already subscribed? Simply sign in below.
Questions or problems? Email firstname.lastname@example.org or call 0860 52 52 00. Got a subscription voucher? Redeem it now
Would you like to comment on this article? Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.